Search Result

Results for "

RNAi

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Enterovirus (1) Factor Xa (3) HBV (1) Lactate Dehydrogenase (2) Liposome (4) Small Interfering RNA (siRNA) (7) Virus Protease (1)
By Research Areas:	Cancer (1) Endocrinology (1) Infection (2) Metabolic Disease (5)
Oligonucleotides:	Pegylated Lipids (1) Cationic Lipids (2) siRNA drugs (8) siRNAs (8)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-132604A

Fazirsiran sodium ARO-AAT sodium	Small Interfering RNA (siRNA)	Metabolic Disease
Fazirsiran sodium is a second-generation *RNAi* agent. Fazirsiran sodium consistes of a cholesterol-conjugated RNAi trigger (chol-RNAi) to selectively degrade Alpha1-antitrypsin (AAT) mRNA by RNAi and a melittin-derived peptide conjugated to N-acetylgalactosamine (NAG) formulated as the excipient EX1 to promote endosomal escape of the chol-RNAi in hepatocytes . Fazirsiran sodium can be used in the study of Alpha-1 Antitrypsin Deficiency (AATD) liver disease.

HY-145411

PEG2000-C-DMG	Liposome	Endocrinology
PEG2000-C-DMG, a pegylated lipid, can be used for the preparation of Onpattro. Onpattro, a hepatically directed investigational RNAi therapeutic agent, harnesses this process to reduce the production of mutant and wild-type transthyretin by targeting the 3′ untranslated region of transthyretin mRNA .

HY-112523A

DMTAP	Liposome	Others
DMTAP is a cationic lipid that can be used for delivery of DNA, RNAi and drugs .

HY-132604

Fazirsiran ARO-AAT	Small Interfering RNA (siRNA)	Metabolic Disease
Fazirsiran (ARO-AAT) is a second-generation *RNAi* agent. Fazirsiran consistes of a cholesterol-conjugated RNAi trigger (chol-RNAi) to selectively degrade Alpha1-antitrypsin (AAT) mRNA by RNAi and a melittin-derived peptide conjugated to N-acetylgalactosamine (NAG) formulated as the excipient EX1 to promote endosomal escape of the chol-RNAi in hepatocytes . Fazirsiran can be used in the study of Alpha-1 Antitrypsin Deficiency (AATD) liver disease.

HY-158305

SM51a	Others	Others
SM51a is a small molecule targeting ligand. SM51a can be linked to the 3' or 5' end of a sense strand or an antisense strand of a DUX4 RNAi agent for promoting it entry into cells .

HY-158306

SM45a	Others	Others
SM45a is a small molecule targeting ligand. SM45a can be linked to the 3' or 5' end of a sense strand or an antisense strand of a DUX4 RNAi agent for promoting it entry into cells .

HY-172328

O12-D3-I3	Liposome	Cancer
O12-D3-I3 is an ionizable cationic lipid. O12-D3-I3 can be used in the generation of lipid nanoparticles (LNPs) for siRNA delivery in vitro and in vivo. LNPs containing O12-D3-I3 enhances LNP endosomal escape for ferroptosis RNAi therapy of cancer .

HY-P10802

ER-DRI	Enterovirus Virus Protease	Infection
ER-DRI is a potent peptide inhibitor that tagets EV-A71. ER-DRI directly bounds to 3A and specifically abrogates viral suppressor of RNAi activity, which unlocked the antiviral RNAi response that is suppressed by 3A. ER-DRI also potently inhibits another enterovirus, Coxsackievirus-A16, dependently of RNAi .

HY-145797

L343	Liposome	Others
L343 is an ionizable cationic lipidoid and can be used to synthetic liposomes for systemic delivery of RNAi therapeutics.

HY-132606

Nedosiran DCR-PHXC	Small Interfering RNA (siRNA) Lactate Dehydrogenase	Metabolic Disease
Nedosiran (DCR-PHXC) is an RNA interference (RNAi) targeting lactate dehydrogenase (LDH). Nedosiran represents an impactful potential therapeutic for primary hyperoxaluria (PH) with end-stage renal disease (ESRD). Nedosiran is a GalNAc-dsRNA conjugate .

HY-132606A

Nedosiran sodium DCR-PHXC sodium	Small Interfering RNA (siRNA) Lactate Dehydrogenase	Metabolic Disease
Nedosiran (DCR-PHXC) sodium is an RNA interference (RNAi) targeting lactate dehydrogenase (LDH). Nedosiran sodium represents an impactful potential therapeutic for primary hyperoxaluria (PH) with end-stage renal disease (ESRD). Nedosiran sodium is a GalNAc-dsRNA conjugate .

HY-132613

Lumasiran sodium	Small Interfering RNA (siRNA)	Metabolic Disease
Lumasiran sodium, an investigational RNA interference *(RNAi)* therapeutic agent, reduces hepatic oxalate production by targeting glycolate oxidase. Lumasiran sodium reduces urinary oxalate excretion, the cause of progressive kidney failure in primary hyperoxaluria type 1 (PH1) .

HY-150224

GalNAc unconjugated/naked Fitusiran sodium	Small Interfering RNA (siRNA) Factor Xa	Others
GalNAc unconjugated/naked Fitusiran (sodium), an small interfering RNA without GalNAc conjugation, specifically targets antithrombin (AT) messenger RNA to lower production of AT in the liver. Fitusiran increases thrombin generation and has the potential for the research of the hemophilia .

HY-132587A

Fitusiran sodium ALN-AT3SC sodium; SAR439774 sodium	Factor Xa	Others
Fitusiran sodium, an small interfering RNA, specifically targets antithrombin (AT) messenger RNA to lower production of AT in the liver. Fitusiran sodium increases thrombin generation and has the potential for the research of the hemophilia .

HY-132587

Fitusiran ALN-AT3SC; SAR439774	Small Interfering RNA (siRNA) Factor Xa	Others
Fitusiran (ALN-AT3SC), an small interfering RNA, specifically targets antithrombin (AT) messenger RNA to lower production of AT in the liver. Fitusiran increases thrombin generation and has the potential for the research of the hemophilia .

HY-116999

IR415	HBV	Infection
IR415 is a potent anti-HBV agent and inhibits HBV replication by blocking the HBx activity. IR415 selectively interacts with HBx (K_d=2 nM) and blocks HBV-mediated RNAi suppression, reverses the inhibitory effect of HBx protein on the activity of the dicer endoribonuclease . HBx: hepatitis B virus X protein.

Cat. No.	Product Name	Type

HY-145411

PEG2000-C-DMG	Drug Delivery
PEG2000-C-DMG, a pegylated lipid, can be used for the preparation of Onpattro. Onpattro, a hepatically directed investigational RNAi therapeutic agent, harnesses this process to reduce the production of mutant and wild-type transthyretin by targeting the 3′ untranslated region of transthyretin mRNA .

HY-112523A

DMTAP	Drug Delivery
DMTAP is a cationic lipid that can be used for delivery of DNA, RNAi and drugs .

HY-145797

L343	Drug Delivery
L343 is an ionizable cationic lipidoid and can be used to synthetic liposomes for systemic delivery of RNAi therapeutics.

Cat. No.	Product Name	Target	Research Area

HY-P10802

ER-DRI	Enterovirus Virus Protease	Infection
ER-DRI is a potent peptide inhibitor that tagets EV-A71. ER-DRI directly bounds to 3A and specifically abrogates viral suppressor of RNAi activity, which unlocked the antiviral RNAi response that is suppressed by 3A. ER-DRI also potently inhibits another enterovirus, Coxsackievirus-A16, dependently of RNAi .

Cat. No.	Product Name		Classification

HY-132604A

Fazirsiran sodium ARO-AAT sodium		siRNAs siRNA drugs
Fazirsiran sodium is a second-generation *RNAi* agent. Fazirsiran sodium consistes of a cholesterol-conjugated RNAi trigger (chol-RNAi) to selectively degrade Alpha1-antitrypsin (AAT) mRNA by RNAi and a melittin-derived peptide conjugated to N-acetylgalactosamine (NAG) formulated as the excipient EX1 to promote endosomal escape of the chol-RNAi in hepatocytes . Fazirsiran sodium can be used in the study of Alpha-1 Antitrypsin Deficiency (AATD) liver disease.

HY-145411

PEG2000-C-DMG		Pegylated Lipids
PEG2000-C-DMG, a pegylated lipid, can be used for the preparation of Onpattro. Onpattro, a hepatically directed investigational RNAi therapeutic agent, harnesses this process to reduce the production of mutant and wild-type transthyretin by targeting the 3′ untranslated region of transthyretin mRNA .

HY-112523A

DMTAP		Cationic Lipids
DMTAP is a cationic lipid that can be used for delivery of DNA, RNAi and drugs .

HY-132613

Lumasiran sodium		siRNAs siRNA drugs
Lumasiran sodium, an investigational RNA interference *(RNAi)* therapeutic agent, reduces hepatic oxalate production by targeting glycolate oxidase. Lumasiran sodium reduces urinary oxalate excretion, the cause of progressive kidney failure in primary hyperoxaluria type 1 (PH1) .

HY-150224

GalNAc unconjugated/naked Fitusiran sodium		siRNAs siRNA drugs
GalNAc unconjugated/naked Fitusiran (sodium), an small interfering RNA without GalNAc conjugation, specifically targets antithrombin (AT) messenger RNA to lower production of AT in the liver. Fitusiran increases thrombin generation and has the potential for the research of the hemophilia .

HY-132587A

Fitusiran sodium ALN-AT3SC sodium; SAR439774 sodium		siRNAs siRNA drugs
Fitusiran sodium, an small interfering RNA, specifically targets antithrombin (AT) messenger RNA to lower production of AT in the liver. Fitusiran sodium increases thrombin generation and has the potential for the research of the hemophilia .

HY-132604

Fazirsiran ARO-AAT		siRNAs siRNA drugs
Fazirsiran (ARO-AAT) is a second-generation *RNAi* agent. Fazirsiran consistes of a cholesterol-conjugated RNAi trigger (chol-RNAi) to selectively degrade Alpha1-antitrypsin (AAT) mRNA by RNAi and a melittin-derived peptide conjugated to N-acetylgalactosamine (NAG) formulated as the excipient EX1 to promote endosomal escape of the chol-RNAi in hepatocytes . Fazirsiran can be used in the study of Alpha-1 Antitrypsin Deficiency (AATD) liver disease.

HY-145797

L343		Cationic Lipids
L343 is an ionizable cationic lipidoid and can be used to synthetic liposomes for systemic delivery of RNAi therapeutics.

HY-132606

Nedosiran DCR-PHXC		siRNAs siRNA drugs
Nedosiran (DCR-PHXC) is an RNA interference (RNAi) targeting lactate dehydrogenase (LDH). Nedosiran represents an impactful potential therapeutic for primary hyperoxaluria (PH) with end-stage renal disease (ESRD). Nedosiran is a GalNAc-dsRNA conjugate .

HY-132606A

Nedosiran sodium DCR-PHXC sodium		siRNAs siRNA drugs
Nedosiran (DCR-PHXC) sodium is an RNA interference (RNAi) targeting lactate dehydrogenase (LDH). Nedosiran sodium represents an impactful potential therapeutic for primary hyperoxaluria (PH) with end-stage renal disease (ESRD). Nedosiran sodium is a GalNAc-dsRNA conjugate .

HY-132587

Fitusiran ALN-AT3SC; SAR439774		siRNAs siRNA drugs
Fitusiran (ALN-AT3SC), an small interfering RNA, specifically targets antithrombin (AT) messenger RNA to lower production of AT in the liver. Fitusiran increases thrombin generation and has the potential for the research of the hemophilia .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.